Reata Pharmaceuticals Inc
NASDAQ:RETA
Reata Pharmaceuticals Inc
Cash from Financing Activities
Reata Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Reata Pharmaceuticals Inc
NASDAQ:RETA
|
Cash from Financing Activities
$90.6m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Financing Activities
-$15.8B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-7%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Financing Activities
-$9.4B
|
CAGR 3-Years
-101%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-24%
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Financing Activities
$26.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Financing Activities
-$4.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
18%
|
CAGR 10-Years
2%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Financing Activities
$3.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Reata Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
90.6m
USD
Based on the financial report for Jun 30, 2023, Reata Pharmaceuticals Inc's Cash from Financing Activities amounts to 90.6m USD.
What is Reata Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-12%
Over the last year, the Cash from Financing Activities growth was 7 190%. The average annual Cash from Financing Activities growth rates for Reata Pharmaceuticals Inc have been -51% over the past three years , -12% over the past five years .